Forum: Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat

Toxicological Sciences

Volumn 103, Issue 1, 2008, Pages 28-34

  Fielden, Mark R ^a   Nie, Alex ^b   Mcmillian, Michael ^b   Elangbam, Chandi S ^c   Trela, Bruce A ^d   Yang, Yi ^d   Dunn, Robert T ^e   Dragan, Yvonne ^f   Fransson stehen, Ronny ^g   Bogdanffy, Matthew ^h   Adams, Stephen P ^i,j   Foster, William R ^i,j   Chen, Shen Jue ^i,j   Rossi, Phil ^k   Kasper, Peter ^l   Jacobson kram, David ^m   Tatsuoka, Kay S ^c   Wier, Patrick J ^c   Gollub, Jeremy ⁿ   Halbert, Donald N ⁿ   Roter, Alan ⁿ   Young, Jamie K ^o   Sina, Joseph F ^p   Marlowe, Jennifer ^q   Martus, Hans Joerg ^q   Aubrecht, Jiri ^r   Olaharski, Andrew J ^a   Roome, Nigel ^s   Nioi, Paul ^p   Pardo, Ingrid ^p   Snyder, Ron ^p   Perry, Richard ^r   Lord, Peter ^b   Mattes, William ^k   Car, Bruce D ^i,j   more..

^a ROCHE BIOSCIENCE   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c GLAXOSMITHKLINE   (United States)

^d ABBOTT LABORATORIES   (United States)

^e AMGEN INC   (United States)

^f ASTRAZENECA   (United Kingdom)

^g ASTRAZENECA R AND D   (Sweden)

^h BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j Bristol Myers Squibb   (United States)

^k CRITICAL PATH INSTITUTE   (United States)

^l Federal Institute for Drugs and Medical Devices   (Germany)

^m CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

ⁿ Entelos Inc   (United States)

^o ELI LILLY AND COMPANY   (United States)

^p MERCK RESEARCH LABORATORIES   (United States)

^q NOVARTIS PHARMA AG   (Switzerland)

^r PFIZER INC   (United States)

^s SANOFI   (France)

more..

Author keywords

Biomarkers; Nongenotoxic; Toxicogenomics

Indexed keywords

BETA NAPHTHOFLAVONE; BIOLOGICAL MARKER; CARBON TETRACHLORIDE; CARCINOGEN; CATECHOL; CHLOROFORM; CLOTRIMAZOLE; ETHINYLESTRADIOL; FLUINDOSTATIN; MEGESTROL; PROGESTERONE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DECISION MAKING; DRUG RESEARCH; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENOTOXICITY; INTERNAL VALIDITY; LIVER CARCINOGENESIS; MALE; MICROARRAY ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTION; QUANTITATIVE ANALYSIS; RAT; REGULATORY MECHANISM; RETROSPECTIVE STUDY; TOXICITY TESTING; TOXICOGENETICS; VALIDATION PROCESS; ANIMAL; CARCINOGEN TESTING; EVALUATION; GENE EXPRESSION PROFILING; GENOMICS; METHODOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; CARCINOGENICITY TESTS; GENE EXPRESSION PROFILING; GENOMICS; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 42149107985     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfn022     Document Type: Article

References (13)

1. Fielden, M. R., Brennan, R., and Gollub, J. (2007). A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol. Sci. 99, 90-100.
2. Guo, L., Lobenhofer, E. K., Wang, C., Shippy, R., Harris, S. C., Zhang, L., Mei, N., Chen, T., Herman, D., Goodsaid, F. M., et al. (2006). Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat. Biotechnol. 24, 1162-1169.
3. Holsapple, M. P., Pitot, H. C., Cohen, S. M., Boobis, A. R., Klaunig, J. E., Pastoor, T., Dellarco, V. L., and Dragan, Y. P. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol. Sci. 89, 51-56.
4. International Conference on Harmonization. (2005). S1C(R1): Dose selection for carcinogenicity studies of pharmaceuticals & limit dose Available at: http://www.ich.org/LOB/media/MEDIA491.pdf. Accessed January 25, 2008.
5. McDonald, J. S. (2004). Human carcinogenic risk evaluation, part IV: Assessment of human risk of cancer from chemical exposure using a global weight-of-evidence approach. Toxicol. Sci. 82, 3-8.
6. Minami, K., Saito, T., Narahara, M., Tomita, H., Kato, H., Sugiyama, H., Katoh, M., Nakajima, M., and Yokoi, T. (2005). Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats. Toxicol. Sci. 87, 296-305.
7. Müller, L., Kikuchi, Y., Probst, G., Schechtman, L., Shimada, H., Sofuni, T., and Tweats, D. (1999). ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: Evolution, reasoning and impact. Mutat. Res. 436, 195-225.
8. Nie, A. Y., McMillian, M., Parker, J. B., Leone, A., Bryant, S., Yieh, L., Bittner, A., Nelson, J., Carmen, A., Wan, J., et al. (2006). Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinog. 45 914-933.
9. Obaseiki-Ebor, E. E., and Obasi, E. E. (1986). Aspects of chloroquine mutagenicity. Mutat. Res. 175, 51-59.
10. Osada, S., Naganawa, A., Misonou, M., Tsuchiya, S., Tamba, S., Okuno, Y., Nishikawa, J., Satoh, K., Imagawa, M., Tsujimoto, G., et al. (2006). Altered gene expression of transcriptional regulatory factors in tumor marker-positive cells during chemically induced hepatocarcinogenesis. Toxicol. Lett. 167, 106-113.
11. Snyder, R. D., and Green, J. W. (2001). A review of the genotoxicity of marketed pharmaceuticals. Mutat. Res. 488, 151-169.
12. Tryndyak, V. P., Muskhelishvili, L., Kovalchuk, O., Rodriguez-Juarez, R., Montgomery, B., Churchwell, M. I., Ross, S. A., Beland, F. A., and Pogribny, I. P. (2006). Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: Implications for tamoxifen-induced hepatocarcinogenesis. Carcinogenesis 27, 1713-1720.
13. Zidek, N., Hellmann, J., Kramer, P. J., and Hewitt, P. G. (2007). Acute hepatotoxicity: A predictive model based on focused illumina microarrays. Toxicol. Sci. 99, 289-302.